You just read:

Eiger Announces First Patient Dosed in Open-Label Extension of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension (PAH)

News provided by

Eiger BioPharmaceuticals, Inc.

Jan 03, 2017, 08:00 ET